1. Home
  2. GCDT vs AEMD Comparison

GCDT vs AEMD Comparison

Compare GCDT & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GCDT

Green Circle Decarbonize Technology Limited Ordinary Shares

HOLD

Current Price

$0.29

Market Cap

5.3M

Sector

Industrials

ML Signal

HOLD

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

SELL

Current Price

$5.15

Market Cap

4.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GCDT
AEMD
Founded
1992
1984
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
4.3M
IPO Year
2022
2008

Fundamental Metrics

Financial Performance
Metric
GCDT
AEMD
Price
$0.29
$5.15
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
★ $13.25
AVG Volume (30 Days)
★ 14.2M
2.3M
Earning Date
11-16-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.23
$0.53
52 Week High
$5.32
$29.45

Technical Indicators

Market Signals
Indicator
GCDT
AEMD
Relative Strength Index (RSI) 42.00 49.22
Support Level N/A $3.20
Resistance Level $0.57 $6.69
Average True Range (ATR) 0.12 0.31
MACD -0.02 -0.26
Stochastic Oscillator 4.38 11.95

Price Performance

Historical Comparison
GCDT
AEMD

About GCDT Green Circle Decarbonize Technology Limited Ordinary Shares

Green Circle Decarbonize Technology Ltd is a company which provides advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services. As an advocate of decarbonization, the Company designs, develops and provides customized energy saving solutions that bring considerable economic benefits to our clients and reduce carbon emissions for a sustainable future.

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.

Share on Social Networks: